PARP1 and neoplasm: Given PARP1’s critical function in cells that mediate anti-tumor immunity, along with reported adverse effects of PARPi treatment such as hematological toxicities [81,82], it seems to be imperative to investigate the direct and immediate effect of PARP inhibitors on immune cells within the context of cancer therapy in greater detail.